Skip to content
ClinCalc Pro
Menu
5-ASA prodrug

Balsalazide sodium

Brand names: Colazide

Balsalazide is an aminosalicylate prodrug used to treat mild to moderate ulcerative colitis and to maintain remission.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a prodrug that is cleaved by colonic bacteria to release the active moiety mesalazine (5-aminosalicylic acid) directly in the colon, where it exerts a topical anti-inflammatory effect on the bowel mucosa.

Prescribing in practice

  • Aminosalicylates can cause blood dyscrasias, and patients should be advised to report unexplained bleeding, bruising, sore throat, fever or malaise that may indicate a blood disorder requiring a full blood count.
  • Renal function should be assessed before and during treatment because mesalazine-related nephrotoxicity, including interstitial nephritis, can occur.
  • Use with caution in patients with salicylate hypersensitivity, and be aware that mesalazine-induced cardiac hypersensitivity and acute intolerance reactions can occur.

Monitoring

Monitor renal function before starting and periodically during treatment, and check a full blood count if a blood dyscrasia is suspected.

Counselling the patient

  • Keep taking it as prescribed, including for maintenance, even when you feel well.
  • Report unexplained bruising, bleeding, sore throat or fever straight away.
  • Tell your prescriber if you have a history of aspirin or salicylate allergy.

Evidence & guidelines

Oral aminosalicylates are recommended first-line in NICE guidance for inducing and maintaining remission in mild to moderate ulcerative colitis.

Reference: NICE NG130; BSG IBD; ECCO; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.